News & Articles

NOSO-502 on track to be the first novel antibiotic class to be introduced into the clinics for 40 years

First high-sensitivity troponin I assay available in the United States enables clinicians to provide improvements in cardiac patient management

To be in with a chance of winning a $500 Amazon voucher, cast your vote by July 23

Alphasonics are optimizing new ultrasonic cleaning systems with ProReveal

Fresh insights into a potentially life-threatening lung disease that causes persistent coughing could pave the way for new therapies

Elenbecestat shown to reduce amyloid beta levels in the brain in phase II clinical study

Roche’s Hemlibra reduced treated bleeds by 96 percent compared to no prophylaxis in phase III HAVEN 3 study in haemophilia A without factor VIII inhibitors

Daiichi Sankyo and Takeda Pharmaceuticals to leverage FDA-approved test for clinical trials and drug development programs

SelectScience brings you scientific and technical takeaways from the 2018 AACR Annual Meeting

FORMA expands translational footprint in neurodegeneration with ARUK Oxford Drug Discovery Institute

First-of-its-kind hematology-based test intended to alert emergency department clinicians to the risk of developing sepsis

Boosting T cell memory may result in long-lasting and effective responses for patients treated with checkpoint blockade immunotherapies

CYC065, an inhibitor of CDK2 and CDK9 kinases, has inhibited tumor growth in some patients with advanced cancers

First human trials examine the impact of dark chocolate consumption on cognition and other brain functions

NYU school of medicine becomes the most recent cancer center to join PanFAM-1 prospective study

The trial demonstrates that first-line pembrolizumab treatment improved overall and progression-free survival rates in patients with metastatic nonsquamous non-small cell lung cancer

The primary endpoint for first-line nivolumab-ipilimumab combo trial indicates improved progression-free survival in patients with advanced non-small cell lung cancer

Expansion of circulating tumor-specific T cells after nivolumab treatment suggests systemic antitumor immunity in patients with resectable lung cancer